Navigation Links
BioMS Medical to present at UBS Global Life Sciences Conference
Date:9/19/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Sept. 19 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the UBS Global Life Sciences Conference in New York.

WHEN: Monday September 22nd at 10:00am (Eastern Time)

WHERE: Grand Hyatt New York, New York

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of comp
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
2. BioMS Medical announces its intention to renew a normal course issuer bid
3. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
4. BioMS Medical Announces Second Quarter 2008 Results
5. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
6. BioMS Medical to present at BMO Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical to present at Jefferies Healthcare Conference
9. BioMS Medical to present at 2008 BIO International Convention
10. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
11. BioMS Medical announces first quarter 2008 results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Arlington, MA (PRWEB) December 18, 2014 ... products for ophthalmology and wound care. The National Eye ... has awarded LayerBio a Phase I SBIR grant to ... , Cataracts are the most common cause of vision ... cause of blindness worldwide. According to Dr. Ken Mandell, ...
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
(Date:12/19/2014)... 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... chronic pain, announced the results of its annual general ... a transformational year in Relmada,s history and it set ... said Sergio Traversa , chief executive officer of ... key financial, human resource and clinical development objectives that ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... that hopes to survive in 2003 has an unambiguous mission ... , ,But how? Funding and resources are strained to the ... (remaining) personnel are having to do the jobs of two ... is it possible under these conditions to do anything fasterand ...
... second installment of an interview with Carl Gulbrandsen ... Foundation (WARF) , Gulbrandsen shares his perspective on how ... He also discusses WARFs unique relationship with the University ... the most successful technologies and patents WARF has licensed. ...
... need to rapidly identify biological agents that could be used ... genome database map by OpGen Inc. , a Madison ... of DNA. , ,One of the most infectious bacteria, Francisella ... referred to as rabbit or deer fever. The bacterium is ...
Cached Biology Technology:Mission Statement 2003: Do More with Less and Do it Faster! 2Mission Statement 2003: Do More with Less and Do it Faster! 3WTN Interview: Carl Gulbrandsen
WARF - A Unique and Successful Technology Transfer Organization 2
WTN Interview: Carl Gulbrandsen
WARF - A Unique and Successful Technology Transfer Organization 3
WTN Interview: Carl Gulbrandsen
WARF - A Unique and Successful Technology Transfer Organization 4
OpGen Database Helps to Reduce Bioterrorist Threat 2
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... in microcontroller (MCU) and touch technology solutions, today launched ... sensors with the widest V cc range ... temperature accuracy and faster I 2 C bus communication ... serial EEPROM memory making them ideal for consumer, industrial, ...
(Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
(Date:11/12/2014)... GARDENS, Fla. , Nov. 12, 2014 ... announced today that its U.are.U ® fingerprint readers ... bakery chain in Central Mexico . ... June 2014 to eliminate payroll issues caused by employees ... to installing the U.are.U fingerprint readers, Montparnasse relied on ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... paralyzing venom ― a complex cocktail of poisonous peptides ... the toxins in this cocktail damage only insects, which ... them to create a safe and ecologically sound pesticide. ... of Plant Sciences has isolated the genetic sequences for ...
... of stem cells in repairing major injuries involving the loss ... delivering stem cells on a polymer scaffold to treat large ... better mechanical properties compared to treatment with the scaffold alone. ... to bone grafting operations. "Massive bone injuries are among ...
... A drug that is already an approved therapy for some ... rare tumor of the gastrointestinal tract, according to a team ... (UPCI). The findings , based on experiments using cell ... Cancer Research . Bortezomib, or Velcade, is used ...
Cached Biology News:A deadly scorpion provides a safe pesticide 2Study shows that delivering stem cells improves repair of major bone injuries in rats 2Study shows that delivering stem cells improves repair of major bone injuries in rats 3Study shows that delivering stem cells improves repair of major bone injuries in rats 4Drug shows promise as new treatment for gut tumor 2
Ideal for chemical processing that requires downward flow of exhaust fumes. Powderful 1200 CFM blower draws fumes into sub-surface bonded charcoal filter for safe removal of organic vapors (final HEP...
... The Label IT siRNA Tracker ... Reagent provides a straight forward approach ... of your design, in an efficient ... tracking experiments. Subcellular localization and functional ...
... The Label IT siRNA Tracker Intracellular ... to directly label and deliver siRNA, of ... manner, for in vitro tracking experiments. Subcellular ... expression can be monitored following introduction of ...
... extracellular matrix (ECM) is an important step ... invasion by adhering to and spreading along ... such as MMP collagenases, dissolve tiny holes ... the blood vessels to allow cancer cells ...
Biology Products: